Quick answers
- What is Susvimo?
- Susvimo is a brand name of Ranibizumab-eqrn, a prescription medicine. The FDA NDC Directory lists 1 Susvimo product in 1 strength and form.
- Who makes Susvimo?
- Genentech Inc holds the FDA application for Susvimo (BLA761197, approved October 22, 2021).
- Is there a generic or store brand of Susvimo?
- Other products of Ranibizumab-eqrn are listed with the FDA, but none in exactly the same strength and form as a Susvimo product.
- Has Susvimo been recalled?
- FDA enforcement reports list 1 recall of Susvimo products; the newest started October 18, 2022. A recall usually concerns specific lots, not every product.
What Susvimo is
Each Susvimo product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Ranibizumab-eqrn · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| ranibizumab 100 mg/mL injection, solution (intravitreal) | Susvimo | None listed | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Ranibizumab-eqrn →
FDA approval
- BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| BLA761197 | Genentech Inc | October 22, 2021 | 1 |
Companies that list Susvimo
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Susvimo products.
- Genentech, Inc.1 product
Recalls
From FDA enforcement reports, matched by the product’s NDC code or label. A recall usually covers specific lots: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
October 18, 2022 · Class III · Terminated · D-0025-2023
Defective Delivery System: Commercial implants do not meet the filed specification for the intended use, a few patients have experienced an issue with the implants that renders it non-functioning.
Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One Susvimo single-dose vial and One Susvimo initial fill needle, NDC 50242-078-55; and b) carton labeled as Susvimo Ocular Implant with In — Genentech Inc
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.